Market Overview

Codexis Q4 Earnings Preview

Related CDXS
The Daily Biotech Pulse: Regulatory Roadblock For Akcea-Ionis, Affimed's Alliance, FDA Nod For Tetraphase's Antibiotic
Benzinga's Top Upgrades, Downgrades For June 19, 2018

Codexis (NASDAQ: CDXS) unveils its next round of earnings Thursday. Here is Benzinga's everything-that-matters guide for today's Q4 earnings announcement.

Earnings and Revenue

Sell-side analysts expect Codexis's EPS to be near 5 cents per share on sales of $22.96 million.

In the same quarter last year, Codexis reported a loss per share of 7 cents on sales of $9.9 million. If the company were to post earnings inline with the consensus estimate when it reports Thursday, EPS would be up 171.43 percent. Sales would be up 130.31 percent from the year-ago period.

The company's reported EPS has stacked up against analyst estimates in the past like this:


Quarter Q3 2017 Q2 2017 Q1 2017 Q4 2016
EPS Estimate -0.17 -0.13 -0.16 -0.11
EPS Actual -0.17 -0.09 -0.13 -0.07

Stock Performance

For a full 12 months, the return has risen by 169.51 percent. Given that these returns are generally positive, long-term shareholders are probably relaxed going into this earnings release. Long-term shareholders are already enjoying 12-month gains prior to the announcement.

Over the past 90 days, analysts have generally adjusted their estimates higher for EPS and revenues. The most common rating from analysts on Codexis stock is a Neutral. The strength of this rating has risen over the past three months.

Conference Call

Codexis's Q4 conference call is scheduled to begin at 4:30 p.m. ET and can be accessed here.

Posted-In: Earnings News Previews Trading Ideas


Related Articles (CDXS)

View Comments and Join the Discussion!

Earnings Preview For MyoKardia

El Pollo Loco Q4 Earnings Preview